Objective: We prospectively investigated 121 renal allograft biopsy specimens performed in our center. Methods: BKVAN was diagnosed by light microscopic examination and a positive immunohistochemistry staining of anti-SV40 large T antibody in a biopsy specimen. Results: Of the 121 patients, nine were diagnosed with BKVAN (7.4%). Nine patients whith BKVN classically presents as allograft dysfunction with an asymptomatic rise in serum creatinine, about 3 to 39 months posttransplant. Urinary decoy cells are positive in two patients (22.2%). The histologic changes of BKVN are not pathognomonic, and can be mistaken for allograft rejection, ie, tubulointerstitial nephritis with varying degrees of inflammatory infiltrates, tubulitis and tubular atrophy, and fibrosis. Typical findings on histology are focal interstitial mononuclear inflammatory cell infiltrates, presence of plasma cells, necrotic tubular epithelium, and presence of homogenous intranuclear inclusion bodies. Immunohistochemistry with SV40 staining were positive in allograft. Graft loss occurred in one patient and the other 8 showed progressive allograft dysfunction. Conclusion: The definitive diagnosis of BKV disease requires renal biopsy. Immunohistochemistry with SV40 staining has been used as an indirect method to document the presence of BKVAN.
References
[1]
S. M. Ji and Z. Tang, “Polyomavirus-Associated Neph- ropathy after Renal Allograft,” Chinese Journal of Nephrology Dialysis & Transplantation, Vol. 15, No. 6, 2006, pp. 572-578.
[2]
P. S. Randhawa and A. J. Demetris, “Nephropathy Due to Polyomavirus Type BK,” New England Journal of Medicine, Vol. 342, 2000, p. 1361.
doi:10.1056/NEJM200005043421809
[3]
S. Hussain, B. A. Bresnahan, E. P. Cohen, et al., “Rapid Kidney Allograft Failure in Patients with Polyoma Virus Nephritis with Prior Treatment with Antilymphocyte Agents,” Clinical Transplantation, Vol. 16, 2002, pp. 43- 47. doi:10.1034/j.1399-0012.2002.00075.x
[4]
H. H. Hirsch, “Polyomavirus BK Nephropathy: A (Re-) Emerging Complication in Renal Transplantation,” American Journal of Transplantation, Vol. 2, 2002, p. 25.
doi:10.1034/j.1600-6143.2002.020106.x
[5]
M. Mengel, M. Marwedel, J. Radermacher, et al., “Incidence of Polyomavirus Nephropathy in Renal Allografts: Influence of Modern Immunosuppressive Drugs,” Ne- phrology Dialysis Transplantation, Vol. 18, 2003, p. 1190. doi:10.1093/ndt/gfg072
[6]
M. S. Sachdeva, R. Nada, V. Jha, et al., “The High Incidence of BK Polyoma Virus Infection among Renal Transplant Recipients in India,” Transplantation, Vol. 77, 2004, p. 429. doi:10.1097/01.TP.0000113163.02039.30
[7]
R. John and A. M. Herzenberg, “Our Approach to a Renal Transplant Biopsy,” Journal of Clinical Pathology, Vol. 63, No. 1, 2010, pp. 26-37. doi:10.1136/jcp.2009.067983
[8]
M. Ahuja, E. P. Cohen, A. M. Dayer, et al., “Polyoma Virus Infection after Renal Transplantation. Use of Im- munostaining as a Guide to Diagnosis,” Transplantation, Vol. 71, 2001, pp. 896-899.
doi:10.1097/00007890-200104150-00013
[9]
B. Celik, R. Shapiro, A. Vats, et al., “Polyomavirus Allograft Nephropathy: Sequential Assessment of Histologic Viral Load, Tubulitis and Graft Function Following Changes in Immunosuppression,” American Journal of Transplantation, Vol. 3, No. 11, 2003, pp. 1378-1382.
doi:10.1046/j.1600-6135.2003.00238.x
[10]
L. C. Racusen, K. Solez, R. B. Colvin, et al., “The Banff 97 Working Classification of Renal Allograft Pathology,” Kidney International, Vol. 55, No. 2, 1999, pp. 713-723.
doi:10.1046/j.1523-1755.1999.00299.x
[11]
G. A. Bǒhmig, M. Exner, A. Habicht, et al., “Capillary C4d Deposition in Kidney Allografts: A Specific Marker of Alloantibody-Dependent Graft Injury,” Journal of the American Society of Nephrology, Vol. 13, 2002, pp. 1091-1099.
[12]
S. Hariharan, “BK Virus Nephritis after Renal Transplan- tation,” Kidney International, Vol. 69, 2006, pp. 655-662.
doi:10.1038/sj.ki.5000040
[13]
H. P. Chen, Z. H. Liu and L. S. Zeng, “Polyomavirus-Associated Nephropathy,” Chinese Journal of Nephrology Dialysis & Transplantation, Vol. 16, No. 4, 2007, pp. 389-393.
[14]
Y. Namba, T. Moriyama, M. Kyo, et al., “Prevalence, Characteristics, and Outcome of BK Virus Nephropathy in Japanese Renal Transplant Patients: Analysis in Proto- col and Episode Biopsies,” Clinical Transplantation, Vol. 19, 2005, pp. 97-101.
doi:10.1111/j.1399-0012.2004.00305.x
[15]
H. H. Hirsch, W. Knowles, M. Dickenmann, et al., “Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant Recipients,” New England Journal of Medicine, Vol. 347, 2002, pp. 488-496.
doi:10.1056/NEJMoa020439
[16]
C. B. Drachenberg, C. O. Beskow, C. B. Cangro, et al., “Human Polyoma Virus in Renal Allograft Biopsies: Morphological Findings and Correlation with Urine Cytology,” Human Pathology, Vol. 30, 1999, pp. 970-977.
doi:10.1016/S0046-8177(99)90252-6
[17]
G. A. Weinberg and A. N. Mian, “BK Virus Nephropathy and Other Polyoma Virus Infections,” The Pediatric Infectious Disease Journal, Vol. 29, 2010, pp. 257-260.
doi:10.1097/INF.0b013e3181d01c6d
[18]
D. Adhania, C. Snopkowski, R. Ding, et al., “Validation of Noninvasive Diagnosis of BK Virus Nephropathy and Identification of Prognostic Biomarkers,” Transplantation, Vol. 90, 2010, pp. 189-197.
doi:10.1097/TP.0b013e3181e2a932
[19]
J. E. Greenlee, S. H. Clawson, R. C. Pheleps and W. G. Stroop, “Distribution of K-Papovavirus in Infected Newborn Mice,” Journal of Comparative Pathology, Vol. 111, 1994, pp. 259-268. doi:10.1016/S0021-9975(05)80004-0
[20]
C. B. Drachenberg, J. C. Papadimitriou, H. H. Hirsch, et al., “Histological Patterns of Polyomavirus Nephropathy: Correlation with Graft Outcome and Viral Load,” American Journal of Transplantation, Vol. 4, 2004, pp. 2082-2092. doi:10.1046/j.1600-6143.2004.00603.x
[21]
B. H. H. Chung, Y. A. Hong, H. G. Kim, et al., “Clinical Usefulness of BK Virus Plasma Quantitative PCR to Pre- vent BK Virus Associated Nephropathy,” Transplant International A 2012 European Society for Organ Trans- plantation, Vol. 25, 2012, pp. 687-695.
[22]
V. Nickeleit, H. H. Hirsch, M. Zeiler, et al., “BK Virus Nephropathy in Renal Transplants-Tubular Necrosis, MHC-Class II Expression and Rejection in a Puzzling Game,” Nephrology Dialysis Transplantation, Vol. 15, 2000, pp. 324-332. doi:10.1093/ndt/15.3.324
[23]
S. M. Ji, L. S. Li, H. P. Chen et al., “Re-Evaluation of Soluble Interleukin-2 Receptor Used in the Diagnosis of Acute Rejection,” Chinese Journal of Nephrology Dialysis & Transplantation, Vol. 5, No. 2, 1996, pp. 17-20.
[24]
D. C. Brennan, I. Agha, D. I. Bohl, et al., “Incidence of BK with Tacrolimus versus Cyclosporine and Impact of Preemptive Immunosuppression Reduction,” American Journal of Transplantation, Vol. 5, 2005, pp. 582-594.
doi:10.1111/j.1600-6143.2005.00742.x
[25]
A. S. Weiss, J. Gralla, L. Chan, et al., “Aggressive Immunosuppression Minimization Reduces Graft Loss Fol- lowing Diagnosis of BK Virus-Associated Nephropathy: A Comparison of Two Reduction Strategies,” Clinical Journal of the American Society of Nephrology, Vol. 3, 2008, pp. 1812-1819. doi:10.2215/CJN.05691207
[26]
R. Rahamimov, S. Lustig, A. Tovar, et al., “BK Polyoma Virus Nephropathy in Kidney Transplant Recipient: The Role of New Immunosuppressive Agents,” Transplantation Proceedings, Vol. 35, 2003, pp. 604-605.
doi:10.1016/S0041-1345(03)00006-X
[27]
P. V. Kadambi, M. A. Josephson, J. Williams, et al., “Treatment of Refractory BK Virus-Associated Neph- ropathy with Cidofovir,” American Journal of Transplantation, Vol. 3, 2003, pp. 186-191.
doi:10.1034/j.1600-6143.2003.30202.x
[28]
M. A. Josephson, D. Gillen, B. Javaid, et al., “Treatment of Renal Allograft Polyoma BK Virus Infection with Leflunomide,” Transplantation, Vol. 81, 2006, pp. 704-710.
doi:10.1097/01.tp.0000181149.76113.50
